Your browser is no longer supported. Please, upgrade your browser.
FIXX Homology Medicines, Inc. daily Stock Chart
FIXX [NASD]
Homology Medicines, Inc.
Index- P/E- EPS (ttm)-2.43 Insider Own1.10% Shs Outstand42.84M Perf Week13.98%
Market Cap887.22M Forward P/E- EPS next Y-2.83 Insider Trans-10.55% Shs Float41.17M Perf Month71.30%
Income-98.80M PEG- EPS next Q-0.68 Inst Own81.69% Short Float7.09% Perf Quarter0.19%
Sales2.10M P/S422.48 EPS this Y-90.80% Inst Trans7.57% Short Ratio10.79 Perf Half Y8.26%
Book/sh5.87 P/B3.53 EPS next Y-9.30% ROA-34.30% Target Price33.40 Perf Year-13.46%
Cash/sh6.30 P/C3.29 EPS next 5Y-9.40% ROE-43.30% 52W Range11.05 - 31.80 Perf YTD-7.38%
Dividend- P/FCF- EPS past 5Y- ROI-31.30% 52W High-34.87% Beta-
Dividend %- Quick Ratio14.70 Sales past 5Y- Gross Margin- 52W Low87.42% ATR1.16
Employees184 Current Ratio14.70 Sales Q/Q-75.00% Oper. Margin- RSI (14)81.45 Volatility8.93% 6.99%
OptionableYes Debt/Eq0.00 EPS Q/Q-77.80% Profit Margin- Rel Volume0.76 Prev Close20.15
ShortableYes LT Debt/Eq0.00 EarningsNov 12 Payout- Avg Volume270.42K Price20.71
Recom1.70 SMA2027.15% SMA5042.43% SMA2005.75% Volume206,118 Change2.78%
Nov-01-19Initiated Oppenheimer Perform
Sep-10-19Initiated Robert W. Baird Outperform
Apr-12-19Initiated Evercore ISI Outperform
Feb-20-19Initiated H.C. Wainwright Buy $36
Jan-07-19Initiated Canaccord Genuity Buy $37
Sep-07-18Initiated B. Riley FBR Neutral $18.50
Dec-13-19 02:44PM  Homology Medicines, Inc. (FIXX): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-03-19 08:30AM  Homology Medicines Announces Appointment of Gabriel M. Cohn, M.D., as Chief Medical Officer GlobeNewswire +6.88%
Nov-26-19 03:00PM  Homology Medicines Announces Peer-Reviewed Publication Demonstrating its AAVHSC Vectors Crossed the Blood-Brain-Barrier and Blood-Nerve-Barrier in NHPs GlobeNewswire
Nov-12-19 07:35PM  Homology Medicines (FIXX) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:09PM  Homology Medicines Reports Third Quarter 2019 Financial Results and Recent Highlights GlobeNewswire
Nov-05-19 10:32AM  Earnings Preview: Homology Medicines (FIXX) Q3 Earnings Expected to Decline Zacks
Oct-28-19 08:07PM  Hedge Funds Have Never Been This Bullish On Homology Medicines, Inc. (FIXX) Insider Monkey
Oct-25-19 08:30AM  Homology Medicines Presents Preclinical Data From Its Investigational PKU Gene Editing Program, Demonstrating Phenotypic Correction and Molecular Confirmation of Editing Precision GlobeNewswire
Oct-21-19 08:30AM  Homology Medicines Presents Data from Investigational PKU and MLD Gene Therapy Programs that Demonstrate Preclinical Proof-of-Concept for Potential One-Time Therapies GlobeNewswire
Sep-30-19 08:49AM  Homology Medicines to Participate in Conferences in October GlobeNewswire
Sep-27-19 07:37AM  Imagine Owning Homology Medicines (NASDAQ:FIXX) And Wondering If The 19% Share Price Slide Is Justified Simply Wall St.
Sep-03-19 08:30AM  Homology Medicines to Participate at Upcoming Investor Conferences GlobeNewswire
Aug-08-19 04:15PM  Homology Medicines Reports Second Quarter 2019 Financial Results and Recent Highlights GlobeNewswire
Aug-05-19 10:31AM  Analysts Estimate Homology Medicines (FIXX) to Report a Decline in Earnings: What to Look Out for Zacks
Aug-01-19 08:30AM  Homology Medicines to Participate at Upcoming Conferences GlobeNewswire
Jul-15-19 04:01PM  Homology Medicines Appoints Alise Reicin, M.D., to the Board of Directors GlobeNewswire
Jun-27-19 04:01PM  Homology Medicines Announces Leadership Updates GlobeNewswire
Jun-25-19 01:45PM  Could The Homology Medicines, Inc. (NASDAQ:FIXX) Ownership Structure Tell Us Something Useful? Simply Wall St.
Jun-17-19 07:05AM  Homology Medicines Presents Data Showing Single Dose HMI-102 Resulted in Long-Term Correction of PKU, Including Reduction of Phe and Increased Brain Neurotransmitters in Murine Model GlobeNewswire
Jun-13-19 08:30AM  Homology Medicines to Present at JMP Securities Life Sciences Conference GlobeNewswire
Jun-10-19 08:30AM  Homology Medicines Initiates Phase 1/2 Study for HMI-102 Gene Therapy Candidate for Adults with PKU and Expects Initial Clinical Results by Year End 2019 GlobeNewswire
May-14-19 09:00AM  Homology Medicines Announces FDA Fast Track Designation for HMI-102 Gene Therapy Development Candidate for Adults with PKU GlobeNewswire
May-13-19 05:55PM  Homology Medicines (FIXX) Reports Q1 Loss, Lags Revenue Estimates Zacks
04:50PM  Homology Medicines: 1Q Earnings Snapshot Associated Press
04:15PM  Homology Medicines Reports First Quarter 2019 Financial Results and Recent Highlights GlobeNewswire
May-09-19 08:45PM  Is Homology Medicines, Inc. (FIXX) A Good Stock To Buy? Insider Monkey
08:30AM  Homology Medicines to Present at Bank of America Merrill Lynch Health Care Conference GlobeNewswire
May-06-19 10:30AM  Homology Medicines (FIXX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks
May-02-19 08:00AM  Homology Medicines Presents Data from Gene Therapy and Gene Editing Programs and Manufacturing Capabilities at ASGCT Meeting GlobeNewswire
Apr-30-19 12:00PM  Homology Medicines Presents Data Demonstrating Suite of Novel AAV Vectors Targeted Key Cell Types for Inherited Retinal Diseases GlobeNewswire
Apr-15-19 01:05PM  Homology Medicines Announces Upcoming Presentations on its Gene Therapy and Gene Editing Platform and Manufacturing Capabilities at the American Society of Gene & Cell Therapy Meeting GlobeNewswire
Apr-09-19 07:08PM  Homology Medicines Announces Pricing of Public Offering of Common Stock GlobeNewswire -20.26%
Apr-08-19 04:10PM  Homology Medicines Announces Proposed Public Offering of Common Stock GlobeNewswire
Apr-04-19 04:05PM  Homology Medicines Presents Preclinical Data from PKU Gene Therapy Program Demonstrating Restored Metabolic Pathway and Increased Neurotransmitter Production GlobeNewswire
07:00AM  Homology Medicines Announces FDA Clearance of Investigational New Drug Application for HMI-102 Gene Therapy Candidate for PKU GlobeNewswire
Apr-02-19 07:12AM  Can You Imagine How Homology Medicines's (NASDAQ:FIXX) Shareholders Feel About The 77% Share Price Increase? Simply Wall St.
Mar-19-19 08:39AM  Homology Medicines to Present at the Alliance for Regenerative Medicine Investor Day GlobeNewswire
Mar-12-19 07:30AM  Homology Medicines: 4Q Earnings Snapshot Associated Press
07:13AM  Homology Medicines Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Recent Accomplishments GlobeNewswire
Mar-06-19 08:30AM  Homology Medicines to Present at Cowen Healthcare Conference GlobeNewswire -5.40%
Mar-01-19 05:38PM  Julian Robertson Buys 2 Stocks as He Slashes Portfolio GuruFocus.com
Jan-07-19 09:25AM  Homology Medicines Achieves 2018 Goals and Prepares PKU Gene Therapy Program for the Clinic with Initial Data Expected in 2019 GlobeNewswire
08:30AM  Homology Medicines Advances First Gene Editing Development Candidate into IND-Enabling Studies for Pediatric Patients with Phenylketonuria GlobeNewswire
Dec-18-18 09:57AM  Is Homology Medicines, Inc. (FIXX) A Good Stock To Buy? Insider Monkey
Dec-16-18 11:16PM  Qatar Fund Building Venture Capital Unit for U.S. Startups Bloomberg
Nov-13-18 05:07PM  Homology Medicines: 3Q Earnings Snapshot Associated Press
04:16PM  Homology Medicines Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-08-18 08:30AM  Homology Medicines to Present at Stifel Healthcare Conference GlobeNewswire
Nov-07-18 07:30AM  Homology Medicines Presents Data on Platforms Ability to Target the Central and Peripheral Nervous System and Therapeutic Potential in the Rare Disease Metachromatic Leukodystrophy GlobeNewswire
Oct-18-18 07:00AM  Homology Medicines Presents Long-Term Efficacy Data of a Single Dose of Gene Therapy Development Candidate for Treatment of Phenylketonuria GlobeNewswire
Oct-01-18 08:30AM  Homology Medicines to Present at Upcoming Conferences PR Newswire
Aug-30-18 08:30AM  Homology Medicines to Participate in Gene Editing Panel at Citi's Biotech Conference PR Newswire
Aug-21-18 05:31AM  Homology Medicines Sees Hammer Chart Pattern: Time to Buy? Zacks +6.13%
Aug-13-18 04:16PM  Homology Medicines Reports Second Quarter 2018 Financial Results PR Newswire
Jul-16-18 04:01PM  Homology Medicines Announces Peer-Reviewed Publication Demonstrating Efficient and Precise In Vivo Gene Editing Capabilities of Nuclease-Free Technology Platform PR Newswire
Jul-05-18 08:30AM  Homology Medicines to Present at the National PKU Alliance Conference PR Newswire
Jun-25-18 07:30AM  Homology Medicines Added to the Russell 3000® and Russell 2000® Indexes PR Newswire
May-18-18 07:30AM  Homology Medicines Presents Data from PKU Gene Therapy Program Demonstrating Long-Term Durability of Treatment in IND-Enabling Studies PR Newswire
May-14-18 04:24PM  Homology Medicines Reports First Quarter 2018 Financial Results PR Newswire
May-10-18 08:30AM  Homology Medicines to Present at Bank of America Merrill Lynch Healthcare Conference PR Newswire
Apr-30-18 12:40PM  Homology Medicines Announces Upcoming Presentations on its Genetic Medicines Platform at the American Society of Gene & Cell Therapy Meeting PR Newswire
Apr-23-18 09:00AM  Homology Medicines to Participate in the World Orphan Drug Congress PR Newswire
Apr-03-18 12:47PM  Should You Be Concerned About Homology Medicines Incs (NASDAQ:FIXX) Shareholders? Simply Wall St. -6.94%
08:30AM  Homology Medicines Announces Closing of Initial Public Offering PR Newswire
Mar-27-18 04:23PM  Homology Medicines Announces Pricing of Initial Public Offering PR Newswire
Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle, and eye in gene editing and gene therapy modalities. Its lead product candidate is HMI-102, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Smith W BradfordCFO, Treasurer & SecretaryDec 02Option Exercise0.646,0003,8406,000Dec 03 04:07 PM
TZIANABOS ARTHURPresident & CEODec 02Sale16.2512,500203,176102,505Dec 03 04:06 PM
Seymour AlbertChief Scientific OfficerDec 02Sale16.239,300150,970163,150Dec 03 04:05 PM
Smith W BradfordCFO, Treasurer & SecretaryDec 02Sale16.216,00097,2660Dec 03 04:07 PM
Smith W BradfordCFO, Treasurer & SecretaryNov 29Option Exercise0.646,0003,8406,000Dec 03 04:07 PM
TZIANABOS ARTHURPresident & CEONov 29Sale16.0412,500200,559115,005Dec 03 04:06 PM
Seymour AlbertChief Scientific OfficerNov 29Sale16.069,300149,390172,450Dec 03 04:05 PM
Smith W BradfordCFO, Treasurer & SecretaryNov 29Sale16.006,00096,0000Dec 03 04:07 PM